GH Research is trading 5.78% up now at $29.82, apparently amid broader risk-on sentiment after cooler-than-expected inflation data; confidence in this explanation is low.

  • No new company-specific announcement was identified for August 14, 2026.
  • Its latest update, an August 6 second-quarter report, highlighted FDA alignment on Phase 3 manufacturing and device plans.
  • Modest pre-market index gains and the lack of a fresh catalyst make the explanation tentative.